The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells
2011

CXCR7's Role in Cancer Cell Migration

publication Evidence: moderate

Author Information

Author(s): Brian A Zabel, Susanna Lewén, Robert D Berahovich, Juan C Jaén, Thomas J Schall

Primary Institution: ChemoCentryx, Inc.

Hypothesis

Does CXCR7 regulate the trans-endothelial migration of cancer cells in response to chemokines?

Conclusion

CXCR7 antagonists may effectively block the migration of certain cancer cells into lymph nodes.

Supporting Evidence

  • CXCL12 significantly enhanced the migration of cancer cells towards other chemokines.
  • CXCR7 antagonists effectively blocked the migration of cancer cells in response to CXCL12.
  • AMD3100, a CXCR4 antagonist, was less effective than CXCR7 antagonists in inhibiting cell migration.

Takeaway

This study shows that a protein called CXCR7 helps cancer cells move into lymph nodes, and blocking it could stop cancer from spreading.

Methodology

The study used a human Burkitt's lymphoma cell line and assessed cell migration through endothelial cell layers in response to various chemokines.

Potential Biases

Potential bias due to authors' affiliations with ChemoCentryx, Inc.

Limitations

The study was conducted using a single cell line and may not represent all cancer types.

Participant Demographics

Human Burkitt's lymphoma cell line NC-37 was used.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1476-4598-10-73

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication